Vertaling van "development and have " (Nederlands → Frans) :

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Novartis ranks as having one of the industry’s most competitive pharmaceuticals development pipelines with 147 projects in clinical development, of which 27 involve new molecular entities in late-stage trials or under regulatory review.
Novartis est considéré comme possédant l’un des pipelines de produits pharmaceutiques les plus concurrentiels de l’industrie avec 147 projets en développement clinique, dont 27 impliquent de nouvelles entités moléculaires qui sont en phase ultime d’essais ou en cours d’examen par les autorités réglementaires.

Members of the Transparency Committee have a significant responsibility: not only because they’ve accepted the mission to oversee good governance in the Agency, but also, primarily, because they have signed up to working on the development of an effective Agency.
Members of the Transparency Committee have a significant responsibility: not only because they’ve accepted the mission to oversee good governance in the Agency, but also, primarily, because they have signed up to working on the development of an effective Agency.

Malaria kills a child under age five every 30 seconds in Africa Only 10% of R&D funds are used for research into 90% of the world’s health problems The NITD was granted USD 20 million in 2006 by the Wellcome Trust, the Singapore Economic Development Board and Medicines for Malaria Venture to initiate joint research on malaria Leprosy has dropped by over 90% since 1985 Deliveries for Coartem have climbed from four million treatments in 2004 to over 60 million in 2006
En Afrique, la malaria tue un enfant de moins de cinq ans toutes les 30 secondes Seuls 10% des fonds consacrés à la recherche sont investis dans les maladies qui représentent 90% des problèmes de santé dans le monde En 2006, l’Institut Novartis pour les maladies tropicales a obtenu du Wellcome Trust, du Singapore Economic Development Board et de Medicines for Malaria Venture USD 20 millions pour initier un programme commun de recherche sur la malaria Depuis 1985, la lèpre a diminué de plus de 90% Entre 2004 et 2006, les livraisons de Coartem sont passées de 4 millions à plus de 60 millions de traitements

“ Without Novartis and its Foundation for Sustainable Development, leprosy would not have been eliminated from Sri Lanka.
« Sans Novartis et sa Fondation pour un développement durable, nous n’aurions pas éradiqué la lèpre du Sri Lanka.

Goodwill and acquired In-Process Research & Development (IPR&D) projects not yet ready for use are subject to impairment review at least annually, or when events have occurred that require an assessment.
Le goodwill et les projets acquis, intégrés dans le processus de recherche et développement et qui ne sont pas encore prêts à être utilisés, font l’objet d’un test de dépréciation au moins annuel ou quand des événements surgissent qui nécessitent de les évaluer.

We continue to strengthen our pipeline and have 58 new molecular entities in development.
Nous continuons de renforcer notre pipeline et avons 58 entités moléculaires nouvelles en développement.

The different projects that have been developed are either based on private initiatives or organised and subsidised on a local level (local authorities, province…).
Les différents projets développés le sont soit sur base d’initiatives privées, soit subsidiées et mises en place à un niveau local (communes, province…).

To achieve results as quickly as possible, a number of levers have been determined by the Central Working Group for the development of the new organisation.
To achieve results as quickly as possible, a number of levers have been determined by the Central Working Group for the development of the new organisation.

Companies developing vaccines have also managed to find their way to “London” (EMEA) for scientific advice.
Companies developing vaccines have also managed to find their way to “London” (EMEA) for scientific advice.